Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
- 6 March 2016
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 101, 75-85
- https://doi.org/10.1016/j.critrevonc.2016.03.007
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysisFuture Oncology, 2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnnals of Oncology, 2014
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialThe Lancet Oncology, 2013
- Methods for Staging Non-small Cell Lung CancerSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapyJournal of Leukocyte Biology, 2013
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry StudiesPLoS Medicine, 2008
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996